Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2023; 14(8): 311-323
Published online Aug 24, 2023. doi: 10.5306/wjco.v14.i8.311
Readmission rates and outcomes in adults with and without COVID-19 following inpatient chemotherapy admission: A nationwide analysis
Philip Kanemo, Keffi Mubarak Musa, Vaishali Deenadayalan, Rafaella Litvin, Olubunmi Emmanuel Odeyemi, Abdultawab Shaka, Naveen Baskaran, Hafeez Shaka
Philip Kanemo, Department of Internal Medicine, Rapides Regional Medical Center, Alexandria, LA 71301, United States
Keffi Mubarak Musa, Department of Medicine, Ahmadu Bello University Teaching Hospital, Zaria 88445, Kaduna, Nigeria
Vaishali Deenadayalan, Rafaella Litvin, Hafeez Shaka, Department of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL 60623, United States
Olubunmi Emmanuel Odeyemi, Department of Internal Medicine, Ladoke Akintola University Teaching Hospital, Ogbomoso 210101, Oyo, Nigeria
Abdultawab Shaka, Department of Medicine, Windsor University School of Medicine, St. Kitts, Frankfort, IL 60423, United States
Naveen Baskaran, Department of Medicine, University of Florida, Gainesville, FL 32610, United States
Author contributions: Kanemo P and Shaka H conceived of the presented idea and designed and proposed the study protocol; Deenadayalan V and Litvin R extracted data from the nationwide readmission database; Shaka A and Baskaran N provided tools for analysis and conducted the analysis; Musa KM, Shaka H and Odeyemi OE interpreted the analysis results and wrote the manuscript; Shaka H and Kanemo P supervised the findings of this work; all authors discussed the results and contributed to the final manuscript.
Institutional review board statement: As the nationwide readmission database data is anonymous and cannot be used to identify patients, institutional review board approval was not required for this study.
Informed consent statement: As the nationwide readmission database data is anonymous and cannot be used to identify patients, informed consent statement was not required for this study.
Conflict-of-interest statement: The authors hereby declare no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Keffi Mubarak Musa, MBBS, Doctor, Research Assistant, Department of Medicine, Ahmadu Bello University Teaching Hospital, Flat 8, street A, Transit Camp, Shika, Zaria 88445, Kaduna, Nigeria. keffimubarakmusa@gmail.com
Received: May 7, 2023
Peer-review started: May 7, 2023
First decision: July 4, 2023
Revised: July 12, 2023
Accepted: August 8, 2023
Article in press: August 8, 2023
Published online: August 24, 2023
Core Tip

Core Tip: Our nationwide study explored care for patients undergoing inpatient chemotherapy during the coronavirus disease 2019 (COVID-19) pandemic. It is the first to analyze factors surrounding hospitalization for such patients. We found a higher readmission rate during the pandemic, with comorbidities posing a greater risk. Surprisingly, COVID-19 infection was not significantly linked to readmission. Hospitalization costs rose, averaging 22952.00 dollars. Our findings would interest the scientific community, hospital managers, and health policymakers. Understanding the pandemic's impact on cancer patients' care can lead to mitigating health policies.